Skip to content
Review Open access

RIPK1 in Alzheimer’s Disease: A Context-Dependent Signaling Hub Linking Aβ, Tau, Neuroinflammation, and Regulated Cell Death

Sep 2026 · Cells · Vol 15 · 0 citations · 65 references
Medicine

TL;DR

It is proposed that RIPK1 is an understudied pathway in Alzheimer’s disease pathogenesis and that defining its cell-type-specific and stage-dependent functions will be essential to determine whether RIPK1 inhibition can be developed as a disease-modifying therapeutic strategy.

Abstract

Alzheimer’s disease is a multifactorial neurodegenerative disorder in which amyloid-β accumulation, tau pathology, neuroinflammation, synaptic dysfunction, vascular injury, and neuronal loss interact across multiple cellular compartments. Although amyloid and tau remain central to disease definition and biomarker staging, growing evidence indicates that inflammatory and regulated cell-death pathways actively shape disease progression. Receptor-interacting protein kinase 1 (RIPK1) has emerged as a context-dependent signaling checkpoint that links inflammatory signaling to cell-fate decisions. In its scaffold and ubiquitinated forms, RIPK1 supports TNFR1-associated NF-κB and MAPK signaling, whereas RIPK1 kinase activation can promote apoptosis and RIPK1-RIPK3-MLKL-dependent necroptosis when regulatory checkpoints fail. In Alzheimer’s disease, RIPK1 signaling has been implicated in disease-associated microglial responses, impaired amyloid-β handling, astrocyte reactivity, tau-associated neuronal stress, neurovascular dysfunction, and necroptotic cell death. Here, we review the molecular regulation of RIPK1; evaluate evidence from human tissue, experimental models, and cellular systems; and discuss how RIPK1 may function as a convergence and amplification node linking amyloid-β, tau, neuroinflammation, and regulated cell death. We also examine the therapeutic rationale for targeting RIPK1, including CNS-penetrant inhibitors, biomarker challenges, timing of intervention, patient selection, and safety considerations. We propose that RIPK1 is an understudied pathway in Alzheimer’s disease pathogenesis and that defining its cell-type-specific and stage-dependent functions will be essential to determine whether RIPK1 inhibition can be developed as a disease-modifying therapeutic strategy.

Read PDF

Similar papers

Review Aug 2026

Pyroptosis in Alzheimer's disease: Mechanisms and neuroinflammatory networks.

Overall, pyroptosis provides a novel framework for understanding the interplay between neuroinflammation and neurodegeneration in AD; however, its cell-type-specific roles, stage-dependent effects, and translational potential remain to be fully elucidated.

Xin-Kai Wu, Qiuyan Ye, Ming-Sheng Zi et al. · 0 citations
Review Open access Sep 2026

Targeted modulation of NF-κB1 in neurodegenerative diseases

Neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis, are characterized by progressive neuronal dysfunction and loss driven by convergent pathological mechanisms such as oxidative stress, mitochondrial impairment, protein misfolding, apo...

Priyanka Banerjee, Rakesh Das, Amartya Sen et al. · 0 citations
Review Open access Aug 2026

Microglial dysfunction and NLRP3 inflammasome signaling in Alzheimer’s disease: mechanistic insights into neuroinflammation and neurodegeneration

Alzheimer's disease (AD) is a progressively debilitating neurodegenerative condition characterized by the accumulation of amyloid-β (Aβ), tau pathology, synaptopathy, and neuron loss. Recent studies suggest that Neuroinflammation is a critical part of the disease process rather than an accompanying feature of the menti...

Almas Meheboob Pathan · 0 citations
Review Open access Aug 2026

Cell Death in Neurodegenerative Diseases: Molecular Mechanisms and Therapeutic Targets

This review examines RCD as an integrated pathogenic network in major NDs as well as evaluating emerging therapeutic strategies that target cell death crosstalk, restore autophagy lysosomal competence, or improve delivery to the central nervous system.

Tianjiao Li, Qian Zhang, Yichen Wu et al. · 0 citations
Open access Sep 2026

Modulation of IKKβ deubiquitination dynamics by CYLD links microglia-neuron crosstalk to be involved in Alzheimer’s disease

Alzheimer’s disease (AD) is an age-related neurodegenerative disorder with limited therapeutic options. Microglia-mediated neuroinflammation plays a critical role in its pathogenesis. Depending on the microenvironment, activated microglia can adopt either a pro-inflammatory or an anti-inflammatory phenotype. Previous...

Qing-Hua Luo, Wei Wang, Xun-Hu Gu et al. · 0 citations
Review Open access Sep 2026

HMGB1 in Amyloid-Beta Pathology: Mechanistic Insights and Therapeutic Implications for Alzheimer’s Disease

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by the accumulation of amyloid-beta (Aβ) plaques and neurofibrillary tangles. Beyond these hallmark pathological features, the complex pathogenesis of AD involves cellular dysfunctions associated with chronic oxidative stress and neuroin...

Song-I. Seol, Ji-Eun Kim, Dashdulam Davaanyam et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.